There is modeling research that doesn't align with claims made here (disclaimer: I know an author): https://www.medrxiv.org/content/10.1101/2020.09.08.20190629v

There is modeling research that doesn't align with claims made here (disclaimer: I know an author): https://www.medrxiv.org/content/10.1101/2020.09.08.20190629v2 https://www.medrxiv.org/content/10.1101/2020.09.08.20190629v... > A highly effective transmission-blocking vaccine prioritized to adults ages 20-49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults over 60 years old.